Liminatus Pharma, Inc. (LIMN) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
LIMN currently has 50.6M outstanding shares. with moderate dilution risk from 23M authorized shares representing 45.4% potential dilution. The company has significantly diluted shareholders by 82.75% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Jul 06, 2026 |
8-K filing: Liminatus Pharma, Inc. entered into an Amended and Restated Merger Agreement to acquire InnocsAI LLC, issuing 11,188,729 shares of common stock and 158,881.1271 shares of Series A Non-Voting Convertible Preferred Stock as consideration. |
51M | 23M |
| Jun 24, 2026 |
S-1 filing: This prospectus relates to the potential resale of up to 20,688,000 shares of common stock issuable upon the exercise of warrants by the Selling Stockholder. |
51M | 23M |
| May 15, 2026 |
10-Q filing | 44.9M shares outstanding |
45M | 8M |
| Mar 31, 2026 |
10-K filing | 44.9M shares outstanding |
45M | 8M |
| Nov 14, 2025 |
10-Q filing | 27.0M shares outstanding |
27M | 26M |
| Oct 06, 2025 |
10-Q filing | 26.0M shares outstanding |
26M | 27M |
| Jul 17, 2025 |
8-K filing: Liminatus Pharma, Inc. issued 350,000 shares of its common stock to Alta Partners, LLC in exchange for the surrender and cancellation of 1,000,000 warrants. |
26M | 27M |
| Jun 24, 2025 |
S-1 filing: Liminatus Pharma, Inc. is registering for resale by certain selling securityholders up to 21,154,961 shares of common stock and the issuance by them of up to 6,900,000 shares of Common Stock that are issuable upon the exercise of the public warrants. |
26M | 27M |
| Jun 02, 2025 |
10-Q filing | 26.0M shares outstanding |
26M | 0 |